2024 年至 2031 年血管支架市場按產品類型、塗層、最終用戶和地區劃分

血管支架市場評估，2024 年至 2031 年

心血管疾病發生率的上升與人口老化、久坐的生活方式和不良的飲食習慣有關。藥物洗脫支架、生物可吸收支架等新型支架技術改善了治療效果，預計2024年市場規模將達到93.8億美元，2031年將達到143.6億美元。

此外，微創手術的興起、醫療保健基礎設施的改善以及創新醫療技術的普及正在推動市場擴張，尤其是在新興地區。優惠的報銷政策和日益增強的血管健康意識也在推動市場成長，預計 2024 年至 2031 年期間的複合年增長率約為 5.47%。

血管支架市場定義/概述

血管支架是一種小型的網狀醫療設備，用於打通和支撐狹窄或阻塞的動脈，以確保治療心血管疾病的正常血流。血管支架通常用於血管成形術中，治療冠狀動脈疾病、週邊動脈疾病和動脈瘤等疾病，有助於維持動脈暢通並降低未來阻塞的風險。血管支架的未來在於生物可吸收支架、藥物洗脫支架和改進塗層的開發，以改善患者的治療效果、減少問題並提供長期益處。微創技術的創新及其在新興國家日益增長的接受度可能會刺激該領域的未來成長。

心血管疾病發生率上升會推動血管支架市場發展嗎？

全球心血管疾病（CVD）負擔不斷增加，推動了對血管支架等有效替代治療方法的需求。根據世界衛生組織 (WHO) 的數據，心血管疾病仍然是全球主要死亡原因，約佔所有死亡人數的 31%。美國疾病管制與預防中心透露，每年約有 655,000 名美國人死於心臟病。

2024年4月，美國疾病管制與預防中心（CDC）將心血管健康列為其公共衛生計畫的優先事項，為研究提供更多資金，並增加獲得血管支架等創新治療方法的機會。這些努力，加上不斷增長的患者數量和不斷改進的技術，正在推動市場向前發展，以滿足全球對支架治療日益增長的需求。

支架血栓風險的不斷增加是否會阻礙血管支架市場的成長？

支架血栓形成風險的增加是一個重大課題，可能會阻礙血管支架市場的成長。支架血栓形成是一種在支架上形成血栓的疾病，它會導致嚴重問題，包括心臟病發作甚至死亡。這種風險引起了醫療保健提供者和患者的擔憂，並可能減少支架的使用，特別是在高風險族群中。因此，醫療保健提供者可能會轉向其他治療方案或更重視術後藥物依從性以降低風險，這可能會減緩市場成長。

此外，這些安全問題可能會導致監管環境更加嚴格，需要對支架技術進行更嚴格的測試和審批流程。製造商可能面臨新的壓力，需要開發更先進的支架，以最大限度地降低血栓風險，從而增加研發成本，並推遲新產品的推出。總體而言，支架在心血管治療中仍然很重要，但隨著對血栓問題認識的不斷提高和風險的增加，可能會限制其市場佔有率，除非支架設計的創新能夠有效解決這些問題。限制。

目錄

第 1 章簡介

• 市場定義
• 市場區隔
• 研究方法

第 2 章執行摘要

• 主要發現 市場概況 市集亮點

第3章 市場概覽

• 市場規模與成長潛力
• 市場趨勢
• 市場推動因素
• 市場限制
• 市場機會
• 波特五力分析

第4章 血管支架市場（依產品類型）

• 冠狀動脈支架
• 外周支架
• 頸動脈支架
• 主動脈支架
• 生物可吸收支架
• 藥物洗脫支架 (DES)

第5章 血管支架市場（依塗層）

• 藥物塗層支架
• 裸金屬支架
• 可生物降解塗層​​支架

第6章 血管支架市場（依最終用戶）

• 醫院 門診手術中心 (ASC)
• 心導管室
• 診所和專科中心

第 7 章 區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利 亞太地區
• 中國
• 日本
• 印度
• 澳大利亞
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第 8 章 市場動態

• 市場推動因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第 9 章 競爭格局

• 大型公司
• 市佔率分析

第10章 公司簡介

• Medtronic plc（Ireland）
• Abbott Laboratories（US）
• Boston Scientific Corporation（US）
• BIOTRONIK SE & Co. KG（Germany）
• B. Braun Melsungen AG（Germany）
• Terumo Corporation（Japan）
• Cook Medical（US）
• Cordis Corporation（US）
• MicroPort Scientific Corporation（China）

第 11 章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第 12 章附錄

• 縮寫列表
• 來源與參考文獻

Vascular Stents Market Valuation - 2024-2031

The increasing prevalence of cardiovascular disease is related to aging populations, sedentary lifestyles, and bad diets. New stent technologies, including as drug-eluting and bioresorbable stents, are improving treatment outcomes is fuelling the USD 9.38 Billion in 2024 and reachingUSD 14.36 Billion by 2031.

Furthermore, the increased number of minimally invasive operations, combined with improved healthcare infrastructure and access to innovative medical technologies, especially in emerging regions, is propelling market expansion. Favorable reimbursement policies and increased awareness of vascular health are also driving market growth is fueling market expected to grow at aCAGR of about 5.47% from 2024 to 2031.

Vascular Stents Market: Definition/ Overview

Vascular stents are small, mesh-like medical devices that open and support restricted or obstructed blood arteries, ensuring normal blood flow in the treatment of cardiovascular disease. They are generally utilized in angioplasty operations to treat disorders such as coronary artery disease, peripheral artery disease, and aneurysms by keeping arteries open and lowering the risk of future blockage. The future of vascular stents is in the development of bioresorbable stents, drug-eluting stents, and improved coatings that improve patient outcomes, reduce problems, and provide long-term advantages. Innovations in minimally invasive procedures, as well as increased acceptance in emerging economies, are likely to fuel future growth in this sector.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Rising Prevalence of Cardiovascular Diseases Propel the Vascular Stents Market?

The global burden of cardiovascular diseases (CVDs) continues to rise, increasing need for effective treatment alternatives such as vascular stents. According to the World Health Organization, CVDs are still the largest cause of death globally, accounting for an estimated 31% of all fatalities. The Centers for Disease Control and Prevention revealed that approximately 655,000 Americans die each year as a result of heart disease.

In April 2024, the US Centers for Disease Control and Prevention (CDC) prioritized cardiovascular health in its public health programs, devoting greater funds to research and improving access to innovative treatments such as vascular stents. These efforts, together with an expanding patient pool and technological improvements, are propelling the market forward and fulfilling rising global demand for stenting treatments.

Will Rising Risk of Stent Thrombosis Complications Hinder the Growth of the Vascular Stents Market?

The increasing risk of stent thrombosis problems is a significant challenge that may impede the growth of the vascular stents market. Stent thrombosis, a disorder in which blood clots form on the stent, can result in major problems, including heart attacks and even death. This danger raises concerns among healthcare practitioners and patients, potentially decreasing stent use, particularly in high-risk groups. As a result, healthcare providers may seek other therapies or place a higher emphasis on post-operative drug adherence to reduce risk, thereby slowing market growth.

Additionally, in reaction to these safety concerns, the regulatory landscape may tighten, resulting in more stringent testing and approval processes for stent technology. Manufacturers may face additional pressure to create more advanced stents that minimize the risk of thrombosis, thereby increasing R&D expenditures and delaying new product introductions. Overall, while stents remain important in cardiovascular treatment, increased knowledge and danger of thrombosis problems may limit market growth unless innovations in stent design effectively address these concerns.

Category-Wise Acumens

Will Increasing Usage of Coronary Stents Propel the Vascular Stents Market?

The increasing use of coronary stents is predicted to greatly boost the vascular stents market. Coronary stents are critical in treating coronary artery disease, which is still a significant cause of death worldwide. The rising prevalence of heart-related illnesses, combined with the expanding use of minimally invasive procedures that use these stents to restore blood flow in clogged arteries, is driving up demand for coronary stents. Furthermore, in April 2024, the European Union increased financing for cardiovascular research, with an emphasis on improving therapeutic technology such as coronary stents. These advancements are driving innovation and fueling market expansion, especially as more patients need stenting treatments to treat cardiovascular problems.

The fastest-growing section is bioresorbable stents, which have the advantage of dissolving over time, lowering long-term problems such restenosis and thrombosis. Bioresorbable stents are rapidly gaining popularity in both developed and emerging economies, owing to continued advances in material science and an increasing preference for least invasive, temporary solutions.

Will Rising Demand for Drug-Coated Stents Fuel the Vascular Stents Market?

The increasing demand for drug-coated stents is projected to drive the vascular stents market. Drug-coated stents, also known as drug-eluting stents, are extremely efficient at reducing restenosis (re-narrowing of arteries) and have become the preferred treatment option for coronary artery disorders. This rising demand is being driven by the superior clinical outcomes that these stents give over bare-metal alternatives, making them indispensable in minimally invasive operations. In July 2024, the FDA approved Abbott's new, enhanced drug-coated stents, which aim to improve long-term results for patients with complicated cardiovascular problems. Meanwhile, in March 2024, the European Medicines Agency issued new rules to speed the clearance procedure for emerging stent technologies, including drug-coated stents, which are expected to boost their global acceptance these developments emphasize the expanding role of drug-coated stents in defining the future of vascular therapy.

Biodegradable coated stents are the fastest-growing class, as they combine the advantages of drug-eluting stents with coatings that disintegrate over time. These stents lessen long-term difficulties and the need for permanent implants, making them more appealing as biodegradable materials develop.

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Vascular Stents Market?

The vascular stents market in North America is expected to increase significantly, owing to the region's rapidly improving healthcare infrastructure. As hospitals and medical centers invest in cutting-edge equipment and technology, the use of minimally invasive procedures, such as vascular stenting, is increasing. This tendency is aided by an aging population and rising prevalence of cardiovascular disorders. According to Verified Market Research, the vascular stents market is predicted to reach USD 9.38 Billion by 2023, rising at a 5.47% CAGR from 2023-2031. The market's growth is also aided by ongoing R&D activities, which result in the launched of more advanced and effective stent technologies.

In August 2024, the United States government provided more funds to expand cardiovascular care infrastructure as part of its healthcare reform projects, with an emphasis on improving access to modern medical treatments such as stenting. In May 2024, Boston Scientific announced the expansion of its vascular stents product line in the United States, highlighting the growing demand for advanced stent technologies, such as drug-eluting and bioresorbable stents, in response to the rising prevalence of cardiovascular disease. These improvements are projected to boost the vascular stents market in North America.

Will Rising Demand for Minimally Invasive Procedures in Asia Pacific Propel the Vascular Stents Market?

The Asia Pacific area is seeing an increase in demand for minimally invasive procedures, which is projected to enhance the vascular stents market. This trend is being driven by reasons such as rising cardiovascular disease prevalence, an aging population, and rising healthcare spending in nations such as China, India, and Japan. The demand for minimally invasive procedures over standard open surgeries is growing due to advantages such as faster recovery times, shorter hospital stays, and lower risk of problems. In January 2024, the Indian Ministry of Health and Family Welfare announced a new plan to increase access to sophisticated cardiac care, which includes funding for vascular stent treatments in public hospitals. This approach is intended to expand the use of stents among low-income individuals.

In April 2024, Medtronic announced plans to increase production of vascular stents in China, citing the growing demand for minimally invasive procedures. These investments and government support are expected to drive the adoption of vascular stents, making Asia Pacific one of the fastest-growing regions in this market.

Competitive Landscape

The competitive landscape of the vascular stents market is shaped by intense competition driven by innovation, technological advancements, and the growing demand for minimally invasive procedures. Smaller companies and regional players are increasingly entering the market, offering cost-effective alternatives and focusing on niche areas like bioresorbable stents or drug-eluting stents. In addition, strategic collaborations, mergers, and acquisitions are common as companies seek to enhance their product portfolios and expand their geographic reach. Regulatory approvals and compliance with healthcare standards also play a critical role, creating competitive advantages for companies that can navigate these processes effectively.

Some of the prominent players operating in the vascular stents market include:

Medtronic plc

Abbott Laboratories

Boston Scientific Corporation

Cook Medical, Inc.

Terumo Corporation

Cardinal Health, Inc.

Braun Melsungen AG

R. Bard, Inc.

MicroPort Scientific Corporation

Endologix, Inc.

Latest Developments

In April 2024, the business debuted a new drug-coated peripheral stent in the Asia Pacific region, with the goal of enhancing treatment outcomes for patients with peripheral artery disease, particularly in diabetic populations.

In March 2024, Terumo launched its next-generation bioresorbable stent in Japan, which dissolves over time to reduce long-term issues including thrombosis and promote natural channel repair.

In February 2024, BIOTRONIK increased their offering with the Orsiro Mission, a drug-eluting stent aimed to improve performance in treating coronary artery blockages. The device has acquired CE clearance and is slated to spread into European markets.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Vascular Stents Market, By Type of Product

• Coronary Stents
• Peripheral Stents
• Carotid Stents
• Aortic Stents
• Bioresorbable stents
• Drug-Eluting Stents (DES)

5. Vascular Stents Market, By Coating

• Drug-Coated Stents
• Bare-Metal Stents
• Biodegradable Coated Stents

6. Vascular Stents Market, By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Cardiac Catheterization Laboratories
• Clinics and specialist Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Medtronic plc (Ireland)
• Abbott Laboratories (US)
• Boston Scientific Corporation (US)
• BIOTRONIK SE & Co. KG (Germany)
• B. Braun Melsungen AG (Germany)
• Terumo Corporation (Japan)
• Cook Medical (US)
• Cordis Corporation (US)
• MicroPort Scientific Corporation (China)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References